TYG Oncology is a biotechnology company that specializes in developing innovative cancer immunotherapies through its proprietary S-TIR™ (Specific Total Immune Remodulation) technology platform. This platform is designed to enhance the patient's immune system, enabling it to mount a robust, specific, and controlled response against cancer cells. The S-TIR™ technology distinguishes itself from existing therapies by its ability to effectively modulate both adaptive and innate immune responses, thereby providing a comprehensive approach to cancer treatment.

The company's lead product candidate, TYG100, is an active checkpoint control immunotherapy (ACCI) specifically targeting gastroenterological cancers, including pancreatic, stomach, and colon cancers. TYG100 utilizes G17 (little gastrin) as a tumor-associated autoantigen, which plays a crucial role in stimulating the immune system to recognize and attack cancer cells. This innovative approach positions TYG Oncology at the forefront of cancer immunotherapy, offering potential new avenues for treatment where traditional therapies may fall short.

United Kingdom

TYG oncology is a biotech company that offers novel cancer immunotherapies based on its unique, proprietary and broadly applicable S-TIR™ (Specific Total Immune Remodulation) technology platform.

Unlike any other currently available therapy, the platform is capable of boosting the patient’s immune system to generate a strong, specific and controlled immune response against cancer.

TYG ONCOLOGY

Company Details